Findings

What do systematic reviews say?

4,811 questions · 70,850 findings · 5,139 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 21.4%GRADE not reported 6,479 · 9.1%Very low 17,330 · 24.5%Low 17,814 · 25.1%Moderate 11,056 · 15.6%High 2,997 · 4.2%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Cerebrolysin or Cerebrolysin‐like agents vs placebo

Death or dependence · people with acute ischemic stroke

The review found no eligible studies for this question.

1 finding from 1 review

Cerebrolysin for acute ischaemic stroke 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cerebrolysin or Cerebrolysin‐like agents vs placebo

Early death (within 2 weeks of stroke onset) · people with acute ischemic stroke

The review found no eligible studies for this question.

1 finding from 1 review

Cerebrolysin for acute ischaemic stroke 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cerebrolysin or Cerebrolysin‐like agents vs placebo

Quality of life · people with acute ischemic stroke

The review found no eligible studies for this question.

1 finding from 1 review

Cerebrolysin for acute ischaemic stroke 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ESWL vs PCNL

Treatment success rate · people (>14 years) with kidney stones

ESWL may leads to lower treatment success rate at 3 months MCID: 5% absolute difference compared with PCNL (low certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 0.67 [0.57, 0.79]
12 studies · 1303 participants
Low

ESWL vs RIRS

Retreatment · people (>14 years) with kidney stones

ESWL probably leads to higher retreatment rate MCID: 3% absolute difference compared with RIRS (moderate certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 6.78 [3.82, 12.04]
9 studies · 1030 participants
Moderate

ESWL vs RIRS

Auxiliary procedures rate MCID: 3% absolute difference · people (>14 years) with kidney stones

ESWL may leads to higher auxiliary procedures rate MCID: 3% absolute difference compared with RIRS (low certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 1.98 [1.14, 3.47]
5 studies · 836 participants
Low

ESWL vs RIRS

Duration of hospital stay MCID: 1 day absolute difference · people (>14 years) with kidney stones

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 591 participants
Moderate

ESWL vs PCNL

Quality of life Assumed MCID: NA · people (>14 years) with kidney stones

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 78 participants
Low

ESWL vs PCNL

Complications MCID: 3% absolute difference · people (>14 years) with kidney stones

ESWL probably leads to lower complications MCID: 3% absolute difference compared with PCNL (moderate certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 0.62 [0.47, 0.82]
13 studies · 1385 participants
Moderate

ESWL vs PCNL

Retreatment · people (>14 years) with kidney stones

ESWL may leads to higher retreatment rate MCID: 3% absolute difference compared with PCNL (low certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 15.53 [6.62, 36.39]
10 studies · 1174 participants
Low

ESWL vs PCNL

Auxiliary procedures rate MCID: 3% absolute difference · people (>14 years) with kidney stones

ESWL probably leads to higher auxiliary procedures rate MCID: 3% absolute difference compared with PCNL (moderate certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 4.17 [2.67, 6.52]
8 studies · 1044 participants
Moderate

ESWL vs PCNL

Duration of hospital stay MCID: 1 day absolute difference · people (>14 years) with kidney stones

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 841 participants
Moderate

ESWL vs RIRS

Treatment success rate · people (>14 years) with kidney stones

ESWL may leads to lower treatment success rate at 3 months MCID: 5% absolute difference compared with RIRS (low certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 0.85 [0.78, 0.93]
13 studies · 1349 participants
Low

ESWL vs RIRS

Quality of life MCID varies by instrument. · people (>14 years) with kidney stones

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 214 participants
Very low

ESWL vs RIRS

Complications MCID: 3% absolute difference · people (>14 years) with kidney stones

It is very uncertain whether ESWL changes complications MCID: 3% absolute difference compared with RIRS (very low certainty).

1 finding from 1 review

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal… 2023 · Cochrane Headline outcomes only
RR 0.93 [0.63, 1.36]
13 studies · 1305 participants
Very low

Home‐based vs centre‐based cardiac rehabilitation

Total mortality Number of deaths · Patients with heart disease

Home‐based showed no clear difference in total mortality Number of deaths compared with centre‐based cardiac rehabilitation (low certainty).

1 finding from 1 review

Home‐based versus centre‐based cardiac rehabilitation 2023 · Cochrane Headline outcomes only
RR 1.19 [0.65, 2.16]
12 studies · 1647 participants
Low

Home‐based vs centre‐based cardiac rehabilitation

Exercise capacity · Patients with heart disease

1 finding from 1 review

Home‐based versus centre‐based cardiac rehabilitation 2023 · Cochrane Headline outcomes only
no estimate extracted
24 studies · 2343 participants
Moderate

Home‐based vs centre‐based cardiac rehabilitation

Withdrawal from the exercise programme Number of completers (participants with data at · Patients with heart disease

Home‐based showed no clear difference in withdrawal from the exercise programme Number of completers… compared with centre‐based cardiac rehabilitation (low certainty).

1 finding from 1 review

Home‐based versus centre‐based cardiac rehabilitation 2023 · Cochrane Headline outcomes only
RR 1.04 [0.99, 1.08]
23 studies · 2638 participants
Low

Home‐based vs centre‐based cardiac rehabilitation

HRQoL Validated measures of HRQoL (e.g. Short Form Health Survey (SF‐36), Sickness Impact Profile, Nottingham Health Profile) · Patients with heart disease

1 finding from 1 review

Home‐based versus centre‐based cardiac rehabilitation 2023 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 2207 participants
Moderate

Intervention not reported

All‐cause mortality (death from any cause)

The intervention showed no clear difference in all‐cause mortality (death from any cause) (high certainty).

1 finding from 1 review

Perioperative glycaemic control for people with diabetes undergoing surgery 2023 · Cochrane Headline outcomes only
RR 1.08 [0.88, 1.33]
18 studies · 2551 participants
High